戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 land (seven with lymphadenopathy, one with a plexiform neurofibroma).
2 e pediatric tumors (eg, low-grade glioma and plexiform neurofibroma).
3 Ki, as well as in the MPNST precursor lesion plexiform neurofibroma.
4 nalysis to measure the change in size of the plexiform neurofibroma.
5  include myeloid leukemia, optic glioma, and plexiform neurofibroma.
6 and to have NF1 and a clinically significant plexiform neurofibroma.
7 ically treated a patient with a debilitating plexiform neurofibroma.
8 firmed RUNX1 protein overexpression in human plexiform neurofibromas.
9 l databases for children with orbitotemporal plexiform neurofibromas.
10 utaneous neurofibromas or clinically obvious plexiform neurofibromas.
11  and neurofibromatosis type 1 (NF1) -related plexiform neurofibromas.
12 sis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas.
13 lind trial randomly assigned adults with NF1-plexiform neurofibroma 1:1 to 28-day cycles of oral selu
14                                              Plexiform neurofibroma, a benign peripheral nerve tumor,
15 ues define the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to deve
16 bal Ink4a/Arf loss and identified paraspinal plexiform neurofibromas and atypical neurofibromas.
17 life, whereas loss in adulthood caused large plexiform neurofibromas and morbidity beginning 4 months
18                            Major superficial plexiform neurofibromas and symptomatic spinal neurofibr
19  objective response rate among patients with plexiform neurofibromas and to assess clinical benefit.
20 n S-100 positive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tum
21                                              Plexiform neurofibromas are a hallmark of NF1 and result
22                                              Plexiform neurofibromas are benign nerve sheath Schwann
23                                              Plexiform neurofibromas are common NF1 tumors carrying a
24                                              Plexiform neurofibromas are one of the most common tumor
25                                              Plexiform neurofibromas are pathognomonic of the disease
26                                              Plexiform neurofibromas are peripheral nerve sheath tumo
27                                   Dermal and plexiform neurofibromas are peripheral nerve sheath tumo
28                                              Plexiform neurofibromas are slow growing benign tumors t
29                                              Plexiform neurofibromas are slow-growing chemoradiothera
30 ptic pathway gliomas (OPGs) and orbitofacial plexiform neurofibromas are two of the more common ophth
31                                   Dermal and plexiform neurofibromas as well as malignant peripheral
32 ases, including the use of MEK inhibitors in plexiform neurofibromas associated with neurofibromatosi
33 with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-ad
34               Patients commonly present with plexiform neurofibromas, benign but debilitating growths
35 es were established from 10 dermal and eight plexiform neurofibromas by selective subculture using gl
36 (NF-1), malignant transformation of internal plexiform neurofibromas carries a poor prognosis, in par
37                  Previous studies found that plexiform neurofibroma formation in a mouse model requir
38 urine models that closely recapitulate human plexiform neurofibroma formation indicate that tumorigen
39 ls, leading to classic nodular cutaneous and plexiform neurofibroma formation that completely recapit
40                           In mouse models of plexiform neurofibroma formation, Nf1 haploinsufficient
41 in which loss of NF1 in Schwann cells drives plexiform neurofibromas formation, additional loss of In
42 dies implicating the hematopoietic system in plexiform neurofibroma genesis, delineate the physiology
43 indicated a role for the microenvironment in plexiform neurofibroma genesis.
44 with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and
45                                              Plexiform neurofibromas have an intermediate range of le
46 ow that selumetinib is effective at treating plexiform neurofibromas in adults with NF1.
47                                       Benign plexiform neurofibromas in NF1 patients can transform sp
48   No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatos
49     Imatinib mesylate could be used to treat plexiform neurofibromas in patients with NF1.
50  the volume burden of clinically significant plexiform neurofibromas in patients with NF1.
51 val overgrowth is caused by the formation of plexiform neurofibromas in the connective tissue of the
52 cursors (SCP), which have been implicated in plexiform neurofibroma initiation.
53                     Extent of orbitotemporal plexiform neurofibroma involvement was assessed clinical
54  of Nf1 resulted in the development of small plexiform neurofibromas late in life, whereas loss in ad
55                               Orbitotemporal plexiform neurofibroma location was classified as isolat
56                                    Thus, the plexiform neurofibroma microenvironment involves a tumor
57 that mast cells underpin inflammation in the plexiform neurofibroma microenvironment of neurofibromat
58 delineate hematopoietic contributions to the plexiform neurofibroma microenvironment, and highlight a
59 han half of NF1 children with orbitotemporal plexiform neurofibromas, most commonly because of ptosis
60 ngineered mouse model that accurately models plexiform neurofibroma-MPNST progression in humans would
61 pies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently
62 pe with neither externally visible cutaneous/plexiform neurofibromas nor other tumors.
63 , and facial structures (orbital-periorbital plexiform neurofibroma [OPPN]) can result in significant
64 M-PNST contained regions of nerve-associated plexiform neurofibromas or atypical neurofibromas and gr
65 uracy of semi-automated tumor volume maps of plexiform neurofibroma (PN) generated by a deep neural n
66                                     Although plexiform neurofibroma (PN) is thought to represent a be
67                                              Plexiform neurofibroma (PN) tumors are a hallmark manife
68 irtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital
69 from within its common and benign precursor, plexiform neurofibroma (PN).
70 ximately 10-30% of patients with NF1 develop plexiform neurofibromas (PN), non-malignant tumours grow
71 actors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatme
72 matic investigation of ECM enrichment during plexiform neurofibroma (pNF) development and identified
73                                              Plexiform neurofibromas (PNFs) are benign nerve tumors d
74                                              Plexiform neurofibromas (PNFs) are benign tumors of the
75 en studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs).
76               Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicell
77                                              Plexiform neurofibromas (PNs) involving the eyelid, orbi
78 fibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significa
79 eurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
80 lop within preexisting benign lesions called plexiform neurofibromas (PNs).
81 bromatosis type 1 and symptomatic inoperable plexiform neurofibromas received oral selumetinib twice
82  placebo-controlled trial in adults with NF1-plexiform neurofibromas, selumetinib achieved a signific
83  for sensitive measurement of orbitotemporal plexiform neurofibroma size, and larger volumes were ass
84 viable therapeutic options for patients with plexiform neurofibromas that cannot be surgically remove
85 eurofibromatosis type 1 (NF1) develop benign plexiform neurofibromas that frequently progress to beco
86    MPNSTs arise from benign peripheral nerve plexiform neurofibromas that originate in the embryonic
87  had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerat
88        In addition, malignant progression of plexiform neurofibromas to malignant peripheral nerve sh
89 nt coincides with enhanced susceptibility to plexiform neurofibroma tumorigenesis.
90 tients with NF1 have cutaneous, diffuse, and plexiform neurofibromas, tumors comprised primarily of S
91 0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or
92 l subjects with amblyopia had orbitotemporal plexiform neurofibroma volumes greater than 10 mL.
93    Amblyopia secondary to the orbitotemporal plexiform neurofibroma was present in 13 subjects (62%)
94 e or decrease from baseline in the volume of plexiform neurofibromas) was monitored by using volumetr
95 reatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elev